Treats acute lymphoblastic leukemia (ALL). ANDA 40385, held by Barr Laboratories. Methotrexate Sodium.
As of Nov 18, 2026, ANDA 40385 (Trexall), held by Barr Laboratories, was first approved by FDA on Mar 21, 2001, with 7 approved supplements and 0 published complete response letters.
TREXALL is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen Treatment of adults with mycosis fungoides Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen Treatment of adults with rheumatoid arthritis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) Treatment of adults with severe psoriasis 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2001 | Original application | Approved |
| TrexallEQ 5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| TrexallEQ 7.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| TrexallEQ 10MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| TrexallEQ 15MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 28Labeling · Standard review | Approved | None posted |
| Jun 14, 2021 | Supplement 21Labeling · Standard review | Approved | None posted |
| Dec 20, 2016 | Supplement 17Labeling · Standard review | Approved | None posted |
| Dec 20, 2016 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 9, 2002 | Supplement 3Labeling | Approved | None posted |
| Jun 3, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Jun 3, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Mar 21, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters